5-methyl-2-(2,5-dimethyl-1H-pyrrol-1-yl)pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-methyl-2-(2,5-dimethyl-1H-pyrrol-1-yl)pyridine
• 英文别名: 2-(2,5-dimethyl-1H-pyrrol-1-yl)-5-methylpyridine；2-(2,5-dimethylpyrrol-1-yl)-5-methylpyridine
• 化学式: C₁₂H₁₄N₂
• mdl: MFCD03228550
• 分子量: 186.257
• InChiKey: UCPKJCXDROIAQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-氨基-5-甲基吡啶 、 2,5-己二酮 在 scandium tris(trifluoromethanesulfonate) 作用下， 反应 0.67h， 以92%的产率得到5-methyl-2-(2,5-dimethyl-1H-pyrrol-1-yl)pyridine
  参考文献：
  名称：

  Sc（OTf）3在无溶剂条件下催化合成Paal-Knorr吡咯的方法

  摘要：

  通过Paal-Knorr缩合反应可以轻松合成N-取代的吡咯，使用简单的方法即可完成。在筛选的不同金属三氟甲磺酸酯中，在温和的反应条件下，1 mol％的Sc（OTf）3有效地促进了反应，从而获得了优异的收率（89-98％）。另外，Sc（OTf）3可以在反应后容易地回收并重复使用而没有明显的活性损失。

  DOI：

  10.1016/j.tetlet.2006.05.085

文献信息

• BENZAZEPIN-2(1H)-ONE DERIVATIVES
  申请人：Boyle Jessica

  公开号：US20080103130A1

  公开（公告）日：2008-05-01

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are agonists at the beta-2 adrenoceptor. They are useful as feed additives for livestock animals.

  式(I)的化合物及其药用可接受的盐是β-2肾上腺素受体的激动剂。它们可用作家畜动物的饲料添加剂。
• [EN] BICYCLIC KINASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE KINASE BICYCLIQUES ET LEURS UTILISATIONS
  申请人：IOMX THERAPEUTICS AG

  公开号：WO2021219731A2

  公开（公告）日：2021-11-04

  The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibitors, the kinase inhibitors of the invention are distinctive; possessing a particular class of heterocyclic moiety. Such kinase inhibitors can display one or more certain properties distinct to their structurally similar kinase inhibitors. The kinase inhibitors of the invention or pharmaceutical compositions comprising them may be used in the treatment of a disorder or condition, such as a proliferative disorder, for example, a leukaemia or solid tumour. In particular, these and other structurally related kinase inhibitors may be used in the treatment of a proliferative disorder - such as a mixed phenotype acute leukaemia (MPAL) - characterised by (inter-alia) the presence of MEF2C protein, a human chromosomal translocation at 11q23, and/or a KMT2A fusion oncoprotein. The kinase inhibitors or pharmaceutical compositions of the invention may be used topically to modulate skin pigmentation in a subject, for example to impart UV protection and reduce skin cancer risk.
• An approach to the Paal–Knorr pyrroles synthesis catalyzed by Sc(OTf)3 under solvent-free conditions
  作者：Jiuxi Chen、Huayue Wu、Zhiguo Zheng、Can Jin、Xingxian Zhang、Weike Su

  DOI：10.1016/j.tetlet.2006.05.085

  日期：2006.7

  A facile synthesis of N-substituted pyrroles by the Paal–Knorr condensation has been accomplished using a simple procedure. Among different metal triflates screened, 1 mol % Sc(OTf)3 efficiently promoted the reaction to give excellent yield (89–98%) under mild reaction conditions. Additionally, Sc(OTf)3 could be recovered easily after the reactions and reused without evident loss in activity.

  通过Paal-Knorr缩合反应可以轻松合成N-取代的吡咯，使用简单的方法即可完成。在筛选的不同金属三氟甲磺酸酯中，在温和的反应条件下，1 mol％的Sc（OTf）3有效地促进了反应，从而获得了优异的收率（89-98％）。另外，Sc（OTf）3可以在反应后容易地回收并重复使用而没有明显的活性损失。